Christopher Bull Granger

Journal Article Am Heart J · January 2026 BACKGROUND: Prior to 2025, Medicare Part D included a coverage gap during which beneficiaries were responsible for substantially higher portions of medication costs. The impact of this on oral anticoagulant (OAC) prescription fills and subsequent stroke in ... Full text Link to item Cite

Embedding Implementation Science in Clinical Trials: A Framework for Academic-Life Science Partnerships.

Journal Article Pharmaceut Med · November 2025 Implementation science offers a systematic approach to bridging the gap between research and clinical practice by promoting the adoption, scale-up, and sustainment of evidence-based therapies. Historically, academic implementation science efforts in the US ... Full text Link to item Cite

Sex-related differences in long-term quality of life after out-of-hospital cardiac arrest: a nationwide cross-sectional survey study.

Journal Article Eur Heart J Acute Cardiovasc Care · October 12, 2025 AIMS: Sex differences in survival and short-term outcomes after out-of-hospital cardiac arrest (OHCA) are well documented, but its impact on long-term health-related quality of life (HRQoL) is unclear. METHODS AND RESULTS: This cross-sectional survey study ... Full text Link to item Cite

Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension.

Journal Article Hypertension · October 2025 Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox-blood pressure control is low and recent trends suggest it ... Full text Link to item Cite

Approach to the Postmarket Evaluation of Consumer Wearable Technologies.

Journal Article JAMA Cardiol · October 1, 2025 IMPORTANCE: Consumer wearable technologies have wide applications, including some that have US Food and Drug Administration clearance for health-related notifications. While wearable technologies may have premarket testing, validation, and safety evaluatio ... Full text Link to item Cite

Racial and Ethnic Representation and Study Engagement in a Siteless Digital Clinical Trial Using a Smartwatch: Findings From the Apple Heart Study.

Journal Article Mayo Clin Proc Digit Health · September 2025 OBJECTIVE: To evaluate differences in study engagement in diverse racial/ethnic groups that have been significantly underrepresented in atrial fibrillation and digital clinical trials. PATIENTS AND METHODS: This was a secondary analysis of participants fro ... Full text Link to item Cite

Characteristics of patients prescribed SGLT-2i and/or GLP-1RA among cardiology clinics in the US: insights from the COORDINATE-diabetes trial.

Journal Article Am J Prev Cardiol · September 2025 BACKGROUND: Antihyperglycemic agents with cardiovascular (CV) benefits, including SGLT-2i and GLP-1RA, are underused in clinical practice, particularly by cardiologists. Understanding the prescribing patterns of these agents by cardiologists may aid in imp ... Full text Link to item Cite

Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial.

Journal Article Europace · September 1, 2025 AIMS: Apixaban was superior to aspirin for the prevention of stroke or systemic embolism in participants with subclinical atrial fibrillation (SCAF) in the Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fi ... Full text Link to item Cite

Long-Term Healthcare Utilization and Outcomes in Patients Hospitalized for Heart Failure With and Without Atrial Fibrillation.

Journal Article Am J Cardiol · August 20, 2025 The long-term association between AF and clinical outcomes, healthcare resource utilization, and healthcare costs among patients with HF remains underexplored. We conducted an exploratory analysis of 5-year outcomes among patients enrolled in the patient-c ... Full text Link to item Cite

Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy.

Journal Article J Am Coll Cardiol · August 12, 2025 BACKGROUND: Whether frail, elderly patients with atrial fibrillation (AF) on a vitamin K antagonist (VKA) should switch to a direct-acting oral anticoagulant (DOAC) was studied in the FRAIL-AF trial and remains controversial. OBJECTIVES: The purpose of thi ... Full text Link to item Cite

Differences in Characteristics and Clinical Outcomes According to Age in Patients Following High-Risk Myocardial Infarction: Insights from PARADISE-MI.

Journal Article Am J Cardiol · August 6, 2025 The prevalence of coronary heart disease is increasing in an aging population. A better understanding of how risk profiles and outcomes differ by age may allow for targeted treatment and prevention strategies. PARADISE-MI randomized 5661 adults without pri ... Full text Link to item Cite

Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: A subgroup analysis of ARTESiA.

Journal Article Heart Rhythm · August 5, 2025 BACKGROUND: The ARTESiA trial randomized patients with a pacemaker (PM), implantable cardioverter-defibrillator (ICD), or implantable cardiac monitor (ICM) and with subclinical atrial fibrillation to either apixaban or aspirin. OBJECTIVE: We aimed to explo ... Full text Link to item Cite

Impact of timing of treatment for cardiac implantable electronic device infections on healthcare utilization and expenditures.

Journal Article Europace · August 4, 2025 AIMS: Early extraction for cardiovascular implantable electronic device (CIED) infections has been associated with longer survival, while the impact on healthcare utilization is unknown. The aim is to evaluate the impact of early extraction on healthcare e ... Full text Link to item Cite

Advancement of the implementation of evidence-based therapies for cardiovascular-kidney-metabolic conditions: A multi-stakeholder perspective.

Journal Article Am Heart J · August 2025 Cardiovascular disease remains the leading cause of mortality and healthcare expenditures in the United States. It is also a major contributor to premature mortality, years lived with disability, and rising healthcare costs around the world. Despite the av ... Full text Link to item Cite

Treatment Times and In-Hospital Mortality Among Patients with ST-Elevation Myocardial Infarction Throughout the Waves of the COVID-19 Pandemic: Lessons Learned

Journal Article Covid · August 1, 2025 Previous studies about the COVID-19 pandemic on STEMI patient outcomes have conflicting results. It remains unclear if this may be attributed to regional differences and/or differences during COVID-19 wave periods. Using the American Heart Association Get ... Full text Cite

Bridging the gap: From early recognition to timely referral for cardiac implantable electronic devices infections.

Journal Article Am J Med · July 17, 2025 An increasing number of patients are living with cardiac implantable electronic devices (CIEDs). When a patient with a CIED is hospitalized with concern for infection or positive blood cultures from any source, recognizing and managing a possible CIED infe ... Full text Link to item Cite

Atrial fibrillation progression in patients with device-detected subclinical atrial fibrillation: Insights from the ARTESiA trial.

Journal Article Heart Rhythm · July 9, 2025 BACKGROUND: The Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Subclinical Atrial Fibrillation (ARTESiA) trial enrolled patients with subclinical atrial fibrillation (SCAF) lasting < 24 hours. OBJECTIVE AND METHODS: We asse ... Full text Link to item Cite

Corrigendum to "Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia." Kidney International 2025;107:169-179.

Journal Article Kidney Int · June 2025 Full text Link to item Cite

Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial.

Journal Article Eur Heart J · May 30, 2025 BACKGROUND AND AIMS: Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndromes. This study ... Full text Link to item Cite

Clinical implications of perioperative and periprocedural myocardial infarction.

Journal Article Nat Rev Cardiol · May 2025 Full text Link to item Cite

NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial.

Journal Article J Card Fail · April 16, 2025 BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with heart failure (HF) hospitalizations and death when measured during a myocardial infarction (MI). However, NT-proBNP concentrations change following the initial ischemic in ... Full text Link to item Cite

Discontinuation of SGLT-2i and GLP-1RA among persons with Type 2 diabetes and atherosclerotic cardiovascular disease treated in US cardiology clinics.

Journal Article Am Heart J · April 2025 BACKGROUND: SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD); for those prescribed, little is known about reasons for discontinuation. METHODS: From the COORDINATE-Diabetes randomized t ... Full text Link to item Cite

Differences in Care and Outcomes in Cardiogenic Shock in Cardiac Intensive Care Units in the United States and Canada: CCCTN Registry Insights.

Journal Article Can J Cardiol · April 2025 BACKGROUND: Mortality in cardiogenic shock (CS) remains high. Significant interhospital heterogeneity in critical care therapies has been described, which reflects the lack of high-quality evidence to guide optimal treatment. We aimed to describe differenc ... Full text Link to item Cite

Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS.

Journal Article JACC Adv · April 2025 BACKGROUND: Studies have demonstrated the safety and efficacy of reducing the dose of apixaban from 5.0 mg to 2.5 mg twice daily in patients with atrial fibrillation (AF) and ≥2 dose-reduction criteria (age ≥80 years, body weight ≤60 kg, serum creatinine ≥ ... Full text Link to item Cite

Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.

Journal Article J Am Coll Cardiol · March 25, 2025 BACKGROUND: Limited data exist on the optimal antithrombotic strategy to minimize total bleeding and ischemic events for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) and atrial fibrillation (AF). OBJECTIVES ... Full text Link to item Cite

Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation.

Journal Article J Am Coll Cardiol · March 25, 2025 BACKGROUND: In patients with atrial fibrillation (AF) the risk of ischemic stroke is central to recommendations for stroke-prevention treatment. OBJECTIVES: The authors evaluated the biomarker-based Age, Biomarkers, Clinical history (ABC)-AF-stroke risk sc ... Full text Link to item Cite

Mortality after high-risk myocardial infarction over the last 20 years: Insights from the VALIANT and PARADISE-MI trials.

Journal Article Eur J Heart Fail · March 2025 AIMS: The temporal changes in clinical profiles and outcomes of high-risk myocardial infarction survivors enrolled in clinical trials are poorly described. This study compares mortality rates, baseline characteristics, and the prognostic impact of therapie ... Full text Link to item Cite

Public awareness of automated external defibrillator (AED)s and their location: Results of a cross-sectional survey in North Carolina.

Journal Article Resusc Plus · March 2025 Full text Link to item Cite

Network Meta-Analysis With Individual Participant-Level Data of Time-to-Event Outcomes Using Cox Regression.

Journal Article Stat Med · February 28, 2025 The accessibility of individual participant-level data (IPD) enhances the evaluation of moderation effects of patient covariates. It facilitates the provision of accurate estimation of intervention effects and confidence intervals by incorporating covariat ... Full text Link to item Cite

Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study.

Journal Article BMJ · February 12, 2025 OBJECTIVE: To evaluate the association between contemporary hormonal contraceptive use and the risk of incident ischaemic stroke and myocardial infarction. DESIGN: Real-world, nationwide, prospective cohort study. SETTING: Denmark, by use of national regis ... Full text Link to item Cite

Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.

Journal Article Am Heart J · February 2025 BACKGROUND: Clinical trials of antithrombotic agents typically use separate time-to-event analyses for bleeding and ischemic events, but this framework has limitations. Days alive and out of hospital (DAOH) is an alternative that may provide additional ins ... Full text Link to item Cite

Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.

Journal Article Lancet Neurol · February 2025 BACKGROUND: People with subclinical atrial fibrillation are at increased risk of stroke, albeit to a lesser extent than those with clinical atrial fibrillation, leading to an ongoing debate regarding the benefit of anticoagulation in these individuals. In ... Full text Link to item Cite

Stuart J. Connolly, MD, April 9, 1949–June 2, 2024

Journal Article Jacc Clinical Electrophysiology · January 1, 2025 Full text Cite

Effects of dialysate potassium concentration of 3.0 mmol/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0 mmol/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia.

Journal Article Kidney Int · January 2025 The optimal approach towards managing serum potassium (sK+) and hemodialysate potassium concentrations is uncertain. To study this, adults receiving hemodialysis for three months or more with hyperkalemia (pre-dialysis sK+ 5.1-6.5 mmol/l) had cardiac monit ... Full text Link to item Cite

Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial

Journal Article LANCET NEUROLOGY · 2025 Full text Cite

AGE AND COMORBIDITIES ASSOCIATED WITH HEALTHCARE UTILIZATION AFTER RECEIVING A SMARTWATCH IRREGULAR PULSE NOTIFICATION SUGGESTIVE OF ATRIAL FIBRILLATION: FINDINGS FROM THE APPLE HEART STUDY

Conference JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY · 2025 Cite

Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry

Preprint · 2025 Full text Cite

Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF.

Journal Article J Am Heart Assoc · December 17, 2024 BACKGROUND: Significant gap remains in the implementation of guideline-directed medical therapy (GDMT) in patients with heart failure after a hospitalization. We aimed to evaluate the use and titration of GDMT at discharge and over a 12-month period after ... Full text Link to item Cite

Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.

Journal Article Eur Heart J · December 7, 2024 BACKGROUND AND AIMS: The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. METHODS: These pre-specified analyses of the ... Full text Link to item Cite

Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease - insights from the Harmony Outcomes trial.

Journal Article Eur J Prev Cardiol · November 27, 2024 INTRODUCTION: Atrial fibrillation and flutter (AF) are common in patients with type 2 diabetes and are associated with worse outcomes. METHODS: Harmony Outcomes was a multicenter, event-driven, double-blind, placebo-controlled trial comparing the effects o ... Full text Link to item Cite

Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.

Journal Article Circulation · November 26, 2024 BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclin ... Full text Link to item Cite

Remote Follow-up in a Heart Failure Pragmatic Trial: Insights From the CONNECT-HF.

Journal Article J Card Fail · November 2024 BACKGROUND: Randomized controlled trials typically require study-specific visits, which can burden participants and sites. Remote follow-up, such as centralized call centers for participant-reported or site-reported, holds promise for reducing costs and en ... Full text Link to item Cite

RAndomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) trial: Study rationale and design.

Journal Article Am Heart J · November 2024 Out-of-hospital cardiac arrest (OHCA) occurs in nearly 350,000 people each year in the United States (US). Despite advances in pre and in-hospital care, OHCA survival remains low and is highly variable across systems and regions. The critical barrier to im ... Full text Open Access Link to item Cite

Public access defibrillator locations and details in Forsyth County, North Carolina: Results of a telephone survey canvas of large businesses to facilitate out-of-hospital cardiac arrest treatment.

Journal Article Am J Emerg Med · November 2024 BACKGROUND: Limited data are available on locations of public access defibrillation programs across communities in the United States, despite their widespread presence. Our goal was to determine publicly available AED locations of large businesses in a mix ... Full text Link to item Cite

Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, and Multimorbidity.

Journal Article JACC Adv · November 2024 BACKGROUND: Patients with atrial fibrillation (AF) after an acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI) with multiple comorbidities are at increased risk for bleeding and ischemic events. OBJECTIVES: This post-h ... Full text Link to item Cite

Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial.

Journal Article Circ Cardiovasc Interv · November 2024 BACKGROUND: In the AUGUSTUS trial (An Open-Label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndr ... Full text Link to item Cite

In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4.

Journal Article Ann Intern Med · November 2024 Lopes RD, Granger CB, Wojdyla DM, et al. Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024;84:354-364. 39019530. ... Full text Link to item Cite

Predictors and outcomes of intracranial hemorrhage in 58,000 patients with atrial fibrillation on oral anticoagulation: insights from COMBINE-AF

Conference European Heart Journal · October 28, 2024 AbstractBackgroundAmong anticoagulated patients with atrial fibrillation (AF), intracranial hemorrhage (ICH) is the leading cause of b ... Full text Cite

Extracranial systemic embolic events in patients with atrial fibrillation: an individual patient-level meta-analysis of 71 683 patients randomized to NOAC vs warfarin from the COMBINE-AF study

Conference European Heart Journal · October 28, 2024 AbstractBackgroundAtrial Fibrillation (AF) poses a significant risk for both ischemic stroke and systemic embolic events (SEE). While ... Full text Cite

Heart failure risk assessment using biomarkers in patients with atrial fibrillation: analysis of 32,041 patients from the COMBINE-AF study

Conference European Heart Journal · October 28, 2024 AbstractIntroductionHeart failure (HF) is one of the most common comorbidities in patients with AF, resulting in a clinical need for r ... Full text Cite

Clinical outcomes in >10,000 Asian vs >61,000 Non-Asian race patients with AF randomized to Warfarin vs DOACs: a patient-level meta-analyses from COMBINE AF

Conference European Heart Journal · October 28, 2024 AbstractBackgroundRandomized data comparing clinical outcomes of atrial fibrillation (AF) patients with Asian vs non-Asian races are l ... Full text Cite

Evaluation of the biomarker-based ABC-AF-bleeding risk score and clinically based bleeding scores in 31,605 patients with atrial fibrillation treated with oral anticoagulation

Conference European Heart Journal · October 28, 2024 AbstractBackgroundInternational guidelines recommend a systematic evaluation of bleeding risk in patients with atrial fibrillation (AF ... Full text Cite

Differences in risk profiles and clinical outcomes according to age in patients with high-risk myocardial infarction: insights from the PARADISE-MI trial

Conference European Heart Journal · October 28, 2024 AbstractIntroductionTemporal declines in rates of rehospitalization and death after acute myocardial infarction (MI) have not been uni ... Full text Cite

Association of contemporary hormonal contraception and the risk of arterial thrombosis

Conference European Heart Journal · October 28, 2024 AbstractBackgroundWhile contemporary hormonal contraception is effective in preventing unwanted pregnancies, its potential link to an ... Full text Cite

The majority of 30-days survivors return to work one-year after in-hospital cardiac arrest

Conference European Heart Journal · October 28, 2024 AbstractBackgroundSurviving in-hospital cardiac arrest poses a significant risk of anoxic brain damage, which can impede survivors’ ab ... Full text Cite

Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF.

Journal Article J Am Coll Cardiol · October 15, 2024 BACKGROUND: Heart failure (HF) is common among patients with atrial fibrillation (AF), and accurate risk assessment is clinically important. OBJECTIVES: The goal of this study was to investigate the incremental prognostic performance of N-terminal pro-B-ty ... Full text Link to item Cite

Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial.

Journal Article Am J Med · October 2024 OBJECTIVE: We aimed to evaluate the safety and efficacy of antithrombotic strategies by age in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention in AUGUSTUS. METHODS: Patients were stratified into 3 age ... Full text Link to item Cite

Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials.

Journal Article JAMA Cardiol · October 1, 2024 IMPORTANCE: Sudden death is a leading cause of death after acute myocardial infarction (AMI). The Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) and Valsartan in Acute Myocardial Inf ... Full text Link to item Cite

Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.

Journal Article Am Heart J · October 2024 BACKGROUND: Our objective was to determine the number of major cardiovascular events (MACE, nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and deaths from any cause that could be prevented across varying nationwide uptake of sema ... Full text Link to item Cite

Effects of 3.0 mEq/L [K+] Dialysate with Sodium Zirconium Cyclosilicate (SZC) vs. 2.0 mEq/L [K+] Dialysate without SZC on Cardiac Arrhythmia Rates

Conference Journal of the American Society of Nephrology · October 2024 Full text Cite

Relationship Between Infarct Artery, Myocardial Injury, and Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction.

Journal Article J Am Heart Assoc · September 17, 2024 BACKGROUND: The extent to which infarct artery impacts the extent of myocardial injury and outcomes in patients with ST-segment-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention is uncertain. METHODS AND RESULTS: ... Full text Link to item Cite

Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS.

Journal Article J Am Coll Cardiol · September 3, 2024 BACKGROUND: The optimal antithrombotic regimen for patients with atrial fibrillation (AF) who had an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is not known. OBJECTIVES: The authors sought to determine which an ... Full text Link to item Cite

Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.

Journal Article J Am Heart Assoc · September 3, 2024 BACKGROUND: Despite oral anticoagulation, patients with atrial fibrillation (AF) remain at risk of ischemic stroke and systemic embolism (SE) events. For patients whose residual risk is sufficiently high, additional therapies might be useful to mitigate st ... Full text Link to item Cite

Stuart J. Connolly, MD, April 9, 1949–June 2, 2024

Journal Article Heart Rhythm · August 1, 2024 Full text Cite

Characteristics and Outcomes of Adults With Congenital Heart Disease in the Cardiac Intensive Care Unit.

Journal Article JACC Adv · August 2024 BACKGROUND: Little is known regarding the characteristics, treatment patterns, and outcomes in patients with adult congenital heart disease (ACHD) admitted to cardiac intensive care units (CICUs). OBJECTIVES: The authors sought to better define the contemp ... Full text Link to item Cite

In MI with preserved LVEF, long-term β-blocker use vs. no use did not reduce all-cause death or MI at 3.5 y.

Journal Article Ann Intern Med · August 2024 Yndigegn T, Lindahl B, Mars K, et al; REDUCE-AMI Investigators. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med. 2024;390:1372-1381. 38587241. ... Full text Link to item Cite

Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.

Journal Article J Am Coll Cardiol · July 23, 2024 BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased ... Full text Link to item Cite

Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Journal Article Eur Heart J Cardiovasc Pharmacother · July 16, 2024 AIMS: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. METHODS AND R ... Full text Link to item Cite

Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.

Journal Article Circulation · July 16, 2024 BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based m ... Full text Link to item Cite

Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial.

Journal Article Circulation · July 2, 2024 Full text Link to item Cite

Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial.

Journal Article Circ Heart Fail · July 2024 Full text Link to item Cite

Combinations of First Responder and Drone Delivery to Achieve 5-Minute AED Deployment in OHCA.

Journal Article JACC Adv · July 2024 BACKGROUND: Defibrillation in the critical first minutes of out-of-hospital cardiac arrest (OHCA) can significantly improve survival. However, timely access to automated external defibrillators (AEDs) remains a barrier. OBJECTIVES: The authors estimated th ... Full text Link to item Cite

Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.

Journal Article JAMA · June 25, 2024 IMPORTANCE: Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure and reduced ejection fraction (HFrEF). OBJECTIVE: To determine whether the effects of RAS blockers ... Full text Link to item Cite

When cardiovascular medicines should be discontinued.

Journal Article Eur Heart J · June 14, 2024 An integral component of the practice of medicine is focused on the initiation of medications, based on clinical practice guidelines and underlying trial evidence, which usually test the addition of novel medications intended for life-long use in short-ter ... Full text Link to item Cite

Reporting quality of heart failure randomized controlled trials 2000-2020: Temporal trends in adherence to CONSORT criteria.

Journal Article Eur J Heart Fail · June 2024 AIM: Heart failure (HF) is a major cause of morbidity and mortality in older adults. Randomized controlled trials (RCTs) inform HF policy and practice, but the accurate interpretation of results is contingent on clear and transparent reporting. The CONsoli ... Full text Link to item Cite

PREVENT equations predicted risk for incident CVD in adults aged 30 to 79 y.

Journal Article Ann Intern Med · June 2024 Khan SS, Matsushita K, Sang Y, et al; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and validation of the American Heart Association's PREVENT equations. C ... Full text Link to item Cite

Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.

Journal Article Diabetes Obes Metab · May 2024 AIM: To analyse the effects of albiglutide, a glucagon-like peptide 1 receptor agonist, on cardiovascular outcomes in older adults aged ≥65 years with type 2 diabetes and cardiovascular disease who participated in the Harmony Outcomes trial (NCT02465515). ... Full text Link to item Cite

Hypertension, microvascular obstruction and infarct size in patients with STEMI undergoing PCI: Pooled analysis from 7 cardiac magnetic resonance imaging studies.

Journal Article Am Heart J · May 2024 BACKGROUND: Mortality after ST-segment elevation myocardial infarction (STEMI) is increased in patients with hypertension. The mechanisms underlying this association are uncertain. We sought to investigate whether patients with STEMI and prior hypertension ... Full text Link to item Cite

Microvascular Obstruction in Patients With Anterior STEMI Treated With Supersaturated Oxygen.

Journal Article J Soc Cardiovasc Angiogr Interv · May 2024 BACKGROUND: Supersaturated oxygen (SSO2) delivered into the left anterior descending coronary artery after percutaneous coronary intervention (PCI) for anterior ST-segment elevation myocardial infarction (STEMI) has been shown to reduce infarct size, but i ... Full text Link to item Cite

KARDIA-3 STUDY DESIGN: ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HIGH CARDIOVASCULAR RISK AND HYPERTENSION INADEQUATELY CONTROLLED BY STANDARD OF CARE ANTIHYPERTENSIVES

Conference Journal of Hypertension · May 2024 Objective:Zilebesiran is an investigational subcutaneous (SC) RNA interference therapeutic that targets synthesis of hepatic angiotensinogen, the most upstream precursor of the renin-angi ... Full text Cite

Cardiac implantable electronic devices and bloodstream infections: management and outcomes.

Journal Article Eur Heart J · April 7, 2024 BACKGROUND AND AIMS: Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an impl ... Full text Link to item Cite

Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.

Journal Article J Am Heart Assoc · April 2, 2024 BACKGROUND: BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve p ... Full text Link to item Cite

GRACE scores or high-sensitivity troponin for timing of coronary angiography in non-ST-elevation acute coronary syndromes.

Journal Article Clin Res Cardiol · April 2024 BACKGROUND: The GRACE risk score is generically recommended by guidelines for timing of invasive coronary angiography without stating which score should be used. The aim was to determine the diagnostic performance of different GRACE risk scores in comparis ... Full text Link to item Cite

Evaluating registry-based trial economics: Results from the STRESS clinical trial.

Journal Article Contemp Clin Trials Commun · April 2024 BACKGROUND: Registry-based trials have the potential to reduce randomized clinical trial (RCT) costs. However, observed cost differences also may be achieved through pragmatic trial designs. A systematic comparison of trial costs across different designs h ... Full text Link to item Cite

Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.

Journal Article Circulation · March 26, 2024 BACKGROUND: Device-detected atrial fibrillation (also known as subclinical atrial fibrillation or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke ... Full text Link to item Cite

Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.

Journal Article Circulation · March 19, 2024 BACKGROUND: The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain. METHODS: We analyzed data from COMBINE AF (A Collaboration Between Multiple Inst ... Full text Link to item Cite

Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI.

Journal Article J Am Coll Cardiol · March 5, 2024 BACKGROUND: Patients who sustain an acute myocardial infarction (AMI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remain at high risk for heart failure (HF), coronary events, an ... Full text Link to item Cite

Regionalization of stroke systems of care in the stroke belt states: The IMPROVE stroke care quality improvement program.

Journal Article Am Heart J · March 2024 BACKGROUND: Despite guidelines and strong evidence supporting intravenous thrombolysis and endovascular thrombectomy for acute stroke, access to these interventions remains a challenge. The objective of the IMPROVE stroke care program was to accelerate acu ... Full text Link to item Cite

Factors influencing support for the implementation of community-based out-of-hospital cardiac arrest interventions in high- and low-performing counties.

Journal Article Resusc Plus · March 2024 AIM OF THE STUDY: Survival to hospital discharge from out-of-hospital cardiac arrest (OHCA) after receiving treatment from emergency medical services (EMS) is less than 10% in the United States. Community-focused interventions improve survival rates, but t ... Full text Open Access Link to item Cite

In adults aged ≥80 y with NSTE-ACS, an invasive vs. conservative strategy improved outcomes at a median 5.3 y.

Journal Article Ann Intern Med · March 2024 Berg ES, Tegn NK, Abdelnoor M, et al; After Eighty Study Investigators. Long-term outcomes of invasive vs conservative strategies for older patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2023;82:2021-2030. 37968019. ... Full text Link to item Cite

Optimizing warfarin dosing for patients with atrial fibrillation using machine learning.

Journal Article Sci Rep · February 24, 2024 While novel oral anticoagulants are increasingly used to reduce risk of stroke in patients with atrial fibrillation, vitamin K antagonists such as warfarin continue to be used extensively for stroke prevention across the world. While effective in reducing ... Full text Link to item Cite

Access to Mobile Health Interventions Among Patients Hospitalized With Heart Failure: Insights Into the Digital Divide From the CONNECT-HF mHealth Substudy.

Journal Article Circ Heart Fail · February 2024 Full text Link to item Cite

Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial.

Journal Article Circulation · January 23, 2024 Full text Link to item Cite

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.

Journal Article N Engl J Med · January 11, 2024 BACKGROUND: Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of str ... Full text Link to item Cite

Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.

Journal Article Eur J Heart Fail · January 2024 AIM: It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor-neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high-risk myocardial infarction (MI) patients. The ... Full text Link to item Cite